| Company
| InsiderPie Expert Score
| P/E ratio
| Gross margin
| EBIT margin
| ROA
| Net income per employee
|
| TTK Healthcare Limited
|
50
/ 100
| 29
| 50.3%
| 11.6%
| 0.0%
| €4.51K
|
| Zhejiang CONBA Pharmaceutical Co.,Ltd.
|
50
/ 100
| 17
| 53.2%
| 11.1%
| 6.8%
| €9.88K
|
| Amgen Inc.
|
53
/ 100
| 24
| 64.5%
| 23.4%
| 7.5%
| €201.51K
|
| PT Kalbe Farma Tbk.
|
50
/ 100
| 344K
| 40.5%
| 12.6%
| 11.6%
| €13.60K
|
| Zhejiang Zhenyuan Share Co., Ltd.
|
50
/ 100
| 61
| 23.1%
| 2.2%
| 1.6%
| €2.89K
|
| Organon & Co.
|
50
/ 100
| 5.3
| 55.0%
| 20.7%
| 3.7%
| €42.71K
|
| Yung Zip Chemical Ind. Co., Ltd.
|
50
/ 100
| 2.4K
| 23.6%
| 1.2%
| 0.0%
| €59.12
|
| Gilead Sciences, Inc.
|
70
/ 100
| 17
| 78.7%
| 36.1%
| 13.9%
| €392.80K
|
| Zhejiang Int'l Group Co.,Ltd.
|
50
/ 100
| 11
| 6.9%
| 2.5%
| 2.8%
| €20.37K
|
| Bayer AG
|
50
/ 100
| -7.9
| 54.9%
| 12.7%
| -3.2%
| -€36.83K
|
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
|
50
/ 100
| 54
| 45.8%
| 4.3%
| 2.0%
| €5.28K
|
| Wooridul Huebrain Limited
|
50
/ 100
| 190
| 40.9%
| 10.5%
| 0.2%
| €8.19K
|
| Abbott India Limited
|
50
/ 100
| 47
| 45.5%
| 25.4%
| 0.0%
| €35.86K
|
| Oscotec Inc.
|
50
/ 100
| 257
| 95.1%
| 8.4%
| 2.7%
| €49.10K
|
| Kyowa Kirin Co., Ltd.
|
51
/ 100
| 34
| 72.6%
| 17.1%
| 3.6%
| €37.03K
|
| Scilex Holding Company
|
50
/ 100
| -0.32
| 70.4%
| -218.6%
| -146.8%
| -€911.66K
|
| Hunan Jingfeng Pharmaceutical Co.,Ltd.
|
50
/ 100
| 34
| 66.0%
| 53.2%
| 17.8%
| €33.07K
|
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
|
50
/ 100
| 29
| 95.3%
| 42.1%
| 13.5%
| €28.10K
|
| EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S.
|
50
/ 100
| 11
| 28.2%
| 3.0%
| 4.1%
| €49.73K
|
| Genovate Biotechnology Co., Ltd.
|
50
/ 100
| 130
| 36.2%
| 2.4%
| 1.2%
| €2.52K
|
| Daewoong Co., Ltd.
|
50
/ 100
| 13
| 45.1%
| 15.3%
| 2.8%
| €132.68K
|
| AbbVie Inc.
|
54
/ 100
| 142
| 76.2%
| 21.8%
| 1.8%
| €37.10K
|
| Biogen Inc.
|
54
/ 100
| 12
| 73.0%
| 25.4%
| 5.5%
| €180.30K
|
| PharmGen Science, Inc.
|
50
/ 100
| 28
| 64.4%
| 5.9%
| 0.9%
| €6.65K
|
| Pfizer Inc.
|
58
/ 100
| 15
| 72.1%
| 26.1%
| 5.2%
| €113.15K
|
| Merck & Co., Inc.
|
48
/ 100
| 12
| 81.2%
| 34.2%
| 14.0%
| €191.58K
|
| Gland Pharma Limited
|
50
/ 100
| 36
| 55.1%
| 20.9%
| 0.0%
| €17.20K
|
| Novo Nordisk A/S
|
56
/ 100
| 21
| 83.9%
| 45.8%
| 23.0%
| €192.09K
|
| Roche Holding AG
|
49
/ 100
| 13
| 73.6%
| 29.1%
| 17.2%
| €169.60K
|
| Marksans Pharma Limited
|
50
/ 100
| 34
| 56.9%
| 22.5%
| 0.0%
| €28.90K
|
| Perseus Proteomics Inc.
|
50
/ 100
| -5.1
| 86.1%
| -688.4%
| -49.7%
| -€197.69K
|
| Santen Pharmaceutical Co., Ltd.
|
48
/ 100
| 19
| 55.5%
| 15.2%
| 7.7%
| €45.97K
|
| Qingdao Baheal Medical Inc.
|
50
/ 100
| 28
| 37.7%
| 9.3%
| 6.8%
| €19.17K
|
| Haw Par Corporation Limited
|
50
/ 100
| 7
| 56.4%
| 27.1%
| 11.5%
| €0.00
|
| Zhangzhou Pientzehuang Pharmaceutical., Ltd
|
50
/ 100
| 50
| 37.5%
| 26.4%
| 13.8%
| €102.99K
|
| Sanofi
|
55
/ 100
| 12
| 71.6%
| 26.6%
| 7.3%
| €110.11K
|
| Eli Lilly and Company
|
52
/ 100
| 42
| 83.0%
| 43.9%
| 16.0%
| €333.94K
|
| Original BioMedicals Co., Ltd.
|
50
/ 100
| -4.7
| -2,842.9%
| -38,901.9%
| -68.4%
| -€189.81K
|
| Kopran Limited
|
50
/ 100
| 29
| 35.4%
| 12.7%
| 0.0%
| €3.90K
|
| Aurora Optoelectronics Co.,Ltd.
|
50
/ 100
| 49
| 14.1%
| -11.5%
| 9.2%
| €25.62K
|
| Otsuka Holdings Co., Ltd.
|
50
/ 100
| 9.5
| 72.1%
| 17.5%
| 10.8%
| €63.23K
|
| SRx Health Solutions Inc.
|
50
/ 100
| -0.96
| 30.9%
| -110.7%
| -46.5%
| -€22.05K
|
| JCR Pharmaceuticals Co., Ltd.
|
50
/ 100
| -13
| 65.4%
| -21.0%
| -5.1%
| -€32.21K
|
| Boai NKY Medical Holdings Ltd.
|
50
/ 100
| 35
| 40.8%
| 20.3%
| 5.6%
| €24.89K
|
| Chugai Pharmaceutical Co., Ltd.
|
50
/ 100
| 32
| 70.3%
| 47.1%
| 17.4%
| €430.01K
|
| NanJing Pharmaceutical Company Limited
|
50
/ 100
| 13
| 6.1%
| 1.9%
| 1.6%
| €13.08K
|
| Johnson & Johnson
|
52
/ 100
| 17
| 67.9%
| 24.4%
| 11.7%
| €139.88K
|
| Lipidor AB (publ)
|
50
/ 100
| -13
| -12,062.7%
| -18,331.3%
| -55.7%
| -€248.55K
|
| AstraZeneca PLC
|
53
/ 100
| 0.37
| 79.4%
| 19.9%
| 7.4%
| €75.58K
|
| Tdspharm
|
50
/ 100
| 21
| 25.3%
| 7.2%
| 5.3%
| €16.04K
|
| Sichuan Kelun Pharmaceutical Co., Ltd.
|
50
/ 100
| 39
| 48.2%
| 12.5%
| 4.2%
| €9.21K
|
| Dechra Pharmaceuticals PLC
|
50
/ 100
| 1.5
| 56.4%
| 7.8%
| 1.9%
| €14.07K
|
| GlaxoSmithKline Pharmaceuticals Limited
|
50
/ 100
| 61
| 58.5%
| 30.3%
| 0.0%
| €27.87K
|
| BCWORLD PHARM. Co., Ltd.
|
50
/ 100
| -12
| 40.5%
| 4.6%
| -2.1%
| -€7.61K
|
| Shangya Technology Co., Ltd.
|
50
/ 100
| -29
| 37.6%
| -29.4%
| -7.0%
| €0.00
|
| Hubei Guangji Pharmaceutical Co., Ltd.
|
50
/ 100
| -9.2
| 22.5%
| -43.9%
| -9.1%
| -€20.23K
|
| Recordati Industria Chimica e Farmaceutica S.p.A.
|
50
/ 100
| 28
| 67.8%
| 25.5%
| 7.9%
| €88.92K
|
| Tonghua Dongbao Pharmaceutical Co., Ltd.
|
50
/ 100
| 13
| 70.9%
| 14.2%
| 15.0%
| €46.35K
|
| Astellas Pharma Inc.
|
48
/ 100
| 31
| 78.4%
| 5.2%
| 2.4%
| €30.21K
|
| SMS Pharmaceuticals Limited
|
50
/ 100
| 30
| 28.4%
| 13.4%
| 0.0%
| €5.75K
|
| GuangYuYuan Chinese Herbal Medicine Co., Ltd.
|
50
/ 100
| 113
| 69.7%
| 7.3%
| 3.7%
| €6.12K
|
| Orion Oyj
|
50
/ 100
| 20
| 61.8%
| 28.5%
| 23.0%
| €95.87K
|
| GSK plc
|
50
/ 100
| 0.18
| 71.4%
| 15.2%
| 5.8%
| €56.89K
|
| Ono Pharmaceutical Co., Ltd.
|
50
/ 100
| 18
| 68.7%
| 11.1%
| 4.2%
| €60.77K
|
| Yifan Pharmaceutical Co., Ltd.
|
50
/ 100
| 43
| 47.6%
| 8.6%
| 3.1%
| €12.01K
|
| Sanofi India Limited
|
50
/ 100
| 40
| 51.6%
| 23.6%
| 29.3%
| €27.87K
|
| CSPC Pharmaceutical Group Limited
|
50
/ 100
| 76
| 70.6%
| 20.3%
| 22.0%
| €49.90K
|
| Jiangsu Hengrui Medicine Co., Ltd.
|
50
/ 100
| 48
| 86.4%
| 27.7%
| 10.9%
| €44.59K
|
| Virbac SA
|
49
/ 100
| 9.7
| 66.6%
| 15.3%
| 15.1%
| €43.04K
|
| Dimed S.A. Distribuidora de Medicamentos
|
50
/ 100
| 11
| 31.1%
| 4.4%
| 3.1%
| €1.60K
|
| Chongqing Lummy Pharmaceutical Co., Ltd.
|
50
/ 100
| -39
| 58.2%
| -15.5%
| -3.9%
| -€12.72K
|
| Pfizer Limited
|
50
/ 100
| 17
| 59.7%
| 34.8%
| 0.0%
| €44.25K
|
| Bristol-Myers Squibb Company
|
52
/ 100
| 17
| 51.0%
| 16.0%
| 6.2%
| €150.96K
|
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
|
50
/ 100
| 50
| 49.0%
| 16.0%
| 7.7%
| €10.54K
|
| Grifols, S.A.
|
50
/ 100
| 15
| 39.5%
| 18.2%
| 1.8%
| €15.21K
|
| Cipla Limited
|
50
/ 100
| 23
| 57.0%
| 22.1%
| 0.0%
| €18.29K
|
| Mayne Pharma Group Limited
|
50
/ 100
| -1.5
| 54.6%
| -8.7%
| -26.4%
| -€179.25K
|
| Daiichi Sankyo Company, Limited
|
51
/ 100
| 23
| 78.5%
| 17.3%
| 8.6%
| €86.34K
|
| TCM Biotech International Corp.
|
50
/ 100
| 178
| 48.0%
| 2.7%
| 3.9%
| €10.19K
|
| Guangdong Jiaying Pharmaceutical Co., Ltd
|
50
/ 100
| 81
| 58.8%
| 11.4%
| 5.1%
| €6.82K
|
| Novartis AG
|
55
/ 100
| 21
| 76.2%
| 30.2%
| 13.1%
| €153.38K
|
| NGL Fine-Chem Limited
|
50
/ 100
| 32
| 50.9%
| 13.1%
| 0.0%
| €2.88K
|
| Firebrick Pharma Limited
|
50
/ 100
| -6
| 78.9%
| -247.6%
| -151.7%
| €0.00
|
